Target to Treatment: Applying a Stewardship Lens to Frontline Therapies in Oncology

Program Description

The rapid expansion of precision medicine in non-small cell lung cancer (NSCLC) has fundamentally shifted the treatment paradigm, as biomarker-directed targeted and immunotherapies consistently demonstrate superior efficacy over traditional chemotherapy. However, this progress introduces a significant challenge for the multidisciplinary team in that many biomarker subgroups now have multiple guideline-recommended frontline options, requiring clinicians to differentiate between therapies with comparable efficacy profiles. To address these complexities, this module provides oncology pharmacists with a structured framework to navigate 11 key biomarker alterations in NSCLC, ranging from EGFR mutations to emerging targets. Through a series of concise videos, participants will learn standardized approaches to systematically weigh efficacy, safety, and cost of treatment, with a specific focus on integrating patient-reported outcomes and toxicity management into real-world decision-making. By applying these practice-based insights and clinical pearls, pharmacists will be equipped to lead evidence-driven therapy selection that optimizes both clinical outcomes and tolerability for patients with NSCLC. The curriculum will be updated quarterly, with videos detailing new FDA approvals and the latest shifts in the biomarker-driven landscape.

Target audience: Oncology Pharmacists, Nurses, Physicians
Type of activity: Application
Release date: July 10, 2026
Expiration date: July 10, 2027
Learner level: Advanced
Time to complete activity: 4.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze efficacy data for frontline therapies across key biomarkers in oncology
• Identify and manage treatment-related adverse effects, applying best practices to optimize patient safety
• Differentiate among guideline-recommended options using a stewardship lens that integrates efficacy, safety, and cost considerations
• Apply clinical pearls and practice-based insights to refine treatment selection and personalize therapy decisions

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 4.5 contact hours (4.5 CEU) under the ACPE universal activity number 0290-0000-26-192-H01-P. The activity is available for CE credit through July 10, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 4.5 contact hours. Eligibility for credits requires full attendance; no partial credits are given.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies

Faculty

Ibrahim Azar, MD, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Astrazeneca, Genmab, Abbvie

Speaker’s Bureau: Foundation1

Other: MJH Life Sciences and Techspert Honoraria

Fawzi Abu Rous, MD, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Johnson & Johnson, Merus, Pfizer, Rigel, Servier

Angel Qin, MD, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: AbbVie, Bristol Myers Squibb, Genentech, Janssen, Pfizer, Regeneron, Summit Therapeutics

Grant/Research Support: AstraZeneca, Genentech, Janssen, Lilly, Merck, Summit Therapeutics

Amanda S. Cass, PharmD, BCPS, BCOP has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Exelixis, BMS, Regeneron, Takeda, Pharmacosmos, Daiichi Sankyo

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Allison Schepers, PharmD, BCOP

Claire Boomershine, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Rose Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms